Takeda’s FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
Positive ReimbursementRecommendationsby Canada's Drug Agency and Institut National d'excellence en Santé et Services Sociaux Takeda Canada Inc. (“Takeda”) is pleased to announce that Health Canada has provided market authorization for FRUZAQLA™(fruquintinib capsules), indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates […]